From Karl Wurm and Guy Scadding's staging to 18F-FDG PET/CT scan phenotyping and far beyond: perspective in the evading history of phenotyping in sarcoidosis

Sarcoidosis is an inflammatory granulomatous disease of unknown etiology involving any organ or tissue along with any combination of active sites, even the most silent ones clinically. The unpredictable nature of the sites involved in sarcoidosis dictates the highly variable natural history of the disease and the necessity to cluster cases at diagnosis based on clinical and/or imaging common characteristics in an attempt to classify patients based on their more homogeneous phenotypes, possibly with similar clinical behavior, prognosis, outcome, and therefore with therapeutic requirements. In the course of the disease's history, this attempt relates to the availability of a means of detection of the sites involved, from the Karl Wurm and Guy Scadding's chest x-ray staging through the ACCESS, the WASOG Sarcoidosis Organ Assessment Instruments, and the GenPhenReSa study to the 18F-FDG PET/CT scan phenotyping and far beyond to new technologies and/or the current “omics.” The hybrid molecular imaging of the 18F-FDG PET/CT scan, by unveiling the glucose metabolism of inflammatory cells, can identify high sensitivity inflammatory active granulomas, the hallmark of sarcoidosis—even in clinically and physiologically silent sites—and, as recently shown, is successful in identifying an unexpected ordered stratification into four phenotypes: (I) hilar–mediastinal nodal, (II) lungs and hilar–mediastinal nodal, (III) an extended nodal supraclavicular, thoracic, abdominal, inguinal, and (IV) all the above in addition to systemic organs and tissues, which is therefore the ideal phenotyping instrument. During the “omics era,” studies could provide significant, distinct, and exclusive insights into sarcoidosis phenotypes linking clinical, laboratory, imaging, and histologic characteristics with molecular signatures. In this context, the personalization of treatment for sarcoidosis patients might have reached its goal.

[1]  C. Bock,et al.  Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation , 2023, Immunity.

[2]  S. Liao,et al.  Multi-Omic Signatures of Sarcoidosis and Progression in Bronchoalveolar Lavage Cells , 2023, bioRxiv.

[3]  J. Grutters,et al.  Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis , 2022, Sarcoidosis Vasculities and Diffuse Lung Diseases.

[4]  M. Walker,et al.  Hypercalcemia: A Review. , 2022, JAMA.

[5]  J. DeWitt,et al.  Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment , 2022, Current Rheumatology Reports.

[6]  D. Jiang,et al.  A transcriptomics-based meta-analysis identifies a cross-tissue signature for sarcoidosis , 2022, Frontiers in medicine.

[7]  Chieh-Yu Lin,et al.  Transcriptional and Immune Landscape of Cardiac Sarcoidosis , 2022, Circulation research.

[8]  J. Grutters,et al.  ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis Patients , 2022, Cells.

[9]  C. D. Dela Cruz,et al.  Emerging insights in sarcoidosis: moving forward through reverse translational research. , 2022, American journal of physiology. Lung cellular and molecular physiology.

[10]  F. Cipollone,et al.  Clinical Features, Histopathology and Differential Diagnosis of Sarcoidosis , 2021, Cells.

[11]  S. Liao,et al.  The landscape of transcriptomic and proteomic studies in sarcoidosis , 2021, ERJ Open Research.

[12]  R. Baughman,et al.  Management of Advanced Pulmonary Sarcoidosis. , 2021, American journal of respiratory and critical care medicine.

[13]  J. Grunewald,et al.  Differences in disease presentation between men and women with sarcoidosis: A cohort study , 2021, Respiratory Medicine.

[14]  H. Dai,et al.  Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019 , 2021, Thorax.

[15]  T. Fingerlin,et al.  Clinical phenotyping in sarcoidosis using cluster analysis , 2021, Respiratory Research.

[16]  Marc A. Judson Granulomatous Sarcoidosis Mimics , 2021, Frontiers in Medicine.

[17]  M. Judson A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist , 2021, Journal of clinical medicine.

[18]  P. Spagnolo,et al.  Genetics in sarcoidosis , 2021, Current opinion in pulmonary medicine.

[19]  J. Grunewald,et al.  Bronchoalveolar lavage fluid cell subsets associate with the disease course in Löfgren's and non-Löfgren's sarcoidosis patients. , 2021, Respiratory medicine.

[20]  Alexander G. Mathioudakis,et al.  ERS clinical practice guidelines on treatment of sarcoidosis , 2021, European Respiratory Journal.

[21]  L. Calandriello,et al.  Novelties in Imaging of Thoracic Sarcoidosis , 2021, Journal of clinical medicine.

[22]  T. Fingerlin,et al.  Genomic biomarkers in chronic beryllium disease and sarcoidosis. , 2021, Respiratory medicine.

[23]  D. Fraidenburg,et al.  Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT , 2021, Frontiers in Medicine.

[24]  F. Akdim,et al.  Effectiveness and safety of infliximab in cardiac Sarcoidosis. , 2021, International journal of cardiology.

[25]  G. Spyropoulos,et al.  Clinical, imaging and functional determinants of sarcoidosis phenotypes in a Greek population , 2021, Journal of Thoracic Disease.

[26]  Xin Xu,et al.  Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study , 2021, Translational lung cancer research.

[27]  Mark M. Davis,et al.  Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 , 2020, Cell.

[28]  I. Annesi-Maesano,et al.  Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort , 2020, European Respiratory Journal.

[29]  Z. Fayad,et al.  Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[30]  M. Judson Screening Sarcoidosis Patients for Occult Disease , 2020, Seminars in Respiratory and Critical Care Medicine.

[31]  M. Becich,et al.  Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis , 2020, European Respiratory Journal.

[32]  E. Arkema,et al.  Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. , 2020, Current opinion in pulmonary medicine.

[33]  C. Montgomery,et al.  Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G × E) interaction studies. , 2020, Current opinion in pulmonary medicine.

[34]  P. Spagnolo,et al.  Looking into the future of sarcoidosis: what is next for treatment? , 2020, Current opinion in pulmonary medicine.

[35]  M. Kallergi,et al.  Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study , 2020, Expert review of respiratory medicine.

[36]  Brian E. Vestal,et al.  Comparative Profiling of the Immune System in Sarcoidosis via CITE-Seq and Flow Cytometry , 2020, Journal of Immunology.

[37]  R. Blankstein,et al.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[38]  M. Scholand,et al.  Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry , 2020, European Respiratory Journal.

[39]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[40]  M. Kallergi,et al.  Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis , 2020, Expert review of respiratory medicine.

[41]  M. Kallergi,et al.  18F-FDG PET/CT in Pulmonary Sarcoidosis:Quantifying Inflammation by the TLG index , 2020, Expert review of respiratory medicine.

[42]  L. Alfredsson,et al.  A Gene–Environment Interaction Between Smoking and Gene polymorphisms Provides a High Risk of Two Subgroups of Sarcoidosis , 2019, Scientific Reports.

[43]  J. Grunewald,et al.  Sarcoidosis , 2019, Nature Reviews Disease Primers.

[44]  J. Grunewald,et al.  Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder , 2019, European Respiratory Journal.

[45]  E. Miller,et al.  Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis. , 2019, JACC. Cardiovascular imaging.

[46]  M. Judson The diagnosis of sarcoidosis. , 2019, Current opinion in pulmonary medicine.

[47]  M. Soussan,et al.  Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. , 2019, Clinical radiology.

[48]  A. Białas,et al.  Sarcoidosis and calcium homeostasis disturbances—Do we know where we stand? , 2019, Chronic respiratory disease.

[49]  J. Grunewald,et al.  Familial aggregation and heritability of sarcoidosis: a Swedish nested case−control study , 2018, European Respiratory Journal.

[50]  J. Grutters,et al.  Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis? , 2018, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[51]  R. Baughman,et al.  It's time to evolve from Scadding: phenotyping sarcoidosis , 2018, European Respiratory Journal.

[52]  J. Milanowski,et al.  Phenotypes of organ involvement in sarcoidosis , 2018, European Respiratory Journal.

[53]  J. Grunewald,et al.  Löfgren's Syndrome: Diagnosis, Management, and Disease Pathogenesis , 2017, Seminars in Respiratory and Critical Care Medicine.

[54]  V. Anttila,et al.  SNP Variants in Major Histocompatibility Complex Are Associated with Sarcoidosis Susceptibility—A Joint Analysis in Four European Populations , 2017, Front. Immunol..

[55]  A. Aggarwal,et al.  Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis. , 2016, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[56]  E. Amin,et al.  Severe Sarcoidosis Phenotypes: An Occupational Hazard? , 2016, Chest.

[57]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[58]  Brian Quinn,et al.  Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates , 2016, BMC Medical Imaging.

[59]  J. Grunewald,et al.  Expanded lung T-bet+RORγT+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype , 2016, European Respiratory Journal.

[60]  S. Walsh,et al.  Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay , 2016, Insights into Imaging.

[61]  M. Nöthen,et al.  High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences. , 2016, American journal of respiratory and critical care medicine.

[62]  L. Hubert,et al.  Llllll Iii Ill Ii Ill1 Lllllll Lllllllll Ill1 Illi Swp 25/88 Issues to Be Addressed Prior to Undertaking Hierarchical Cluster Analysis A-prtort Weighting of Attributes? , 2000 .

[63]  P. Spagnolo,et al.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis , 2015, Clinical Reviews in Allergy & Immunology.

[64]  P. Spagnolo Sarcoidosis: a Critical Review of History and Milestones , 2015, Clinical Reviews in Allergy & Immunology.

[65]  C. Lindskog,et al.  Proteomic profiling reveals autoimmune targets in sarcoidosis. , 2015, American journal of respiratory and critical care medicine.

[66]  M. Gazouli,et al.  Relationship between tumor necrosis factor-α (TNFA) gene polymorphisms and cardiac sarcoidosis. , 2014, In vivo.

[67]  Rajender Kumar,et al.  Ocular sarcoidosis: does (18)F-FDG PET/CT have any role? , 2014, Clinical nuclear medicine.

[68]  A. Prasse,et al.  The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. , 2014, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[69]  A. Gabrielsen,et al.  HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis. , 2014, Tissue antigens.

[70]  A. Nicholson,et al.  An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. , 2014, The Lancet. Respiratory medicine.

[71]  A. Dua,et al.  Images in clinical medicine. Heerfordt's syndrome, or uveoparotid fever. , 2013, The New England journal of medicine.

[72]  J. Grutters,et al.  Imaging the inflammatory activity of sarcoidosis , 2012, European Respiratory Journal.

[73]  A. Prasse,et al.  Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[74]  K. Cederlund,et al.  Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients , 2010, Respiratory research.

[75]  D. Rontogianni,et al.  The many faces of sarcoidosis: asymptomatic muscle mass mimicking giant-cell tumor , 2009, Rheumatology International.

[76]  S. Lofgren Primary pulmonary sarcoidosis. II. Clinical course and prognosis. , 2009, Acta medica Scandinavica.

[77]  J. Grunewald,et al.  Löfgren's syndrome: human leukocyte antigen strongly influences the disease course. , 2009, American journal of respiratory and critical care medicine.

[78]  S. Papiris,et al.  Subcutaneous Sarcoidosis Masquerading as Cellulitis , 2008, Dermatology.

[79]  A. Constantinesco,et al.  18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[80]  A. Prasse,et al.  Phenotyping sarcoidosis from a pulmonary perspective. , 2008, American journal of respiratory and critical care medicine.

[81]  M. Rossman,et al.  Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis). , 2007, Proceedings of the American Thoracic Society.

[82]  R. Elston,et al.  Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study , 2007, Genes and Immunity.

[83]  P. Spagnolo,et al.  Genetics of sarcoidosis. , 2007, Clinics in dermatology.

[84]  Y. Nishiyama,et al.  Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[85]  Bryan Langholz,et al.  Case–Cohort Study , 2005 .

[86]  M. Iannuzzi,et al.  HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. , 2003, American journal of human genetics.

[87]  G. McLennan,et al.  Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[88]  R. Baughman,et al.  Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[89]  R. Loddenkemper,et al.  Clinical findings in 715 patients with newly detected pulmonary sarcoidosis--results of a cooperative study in former West Germany and Switzerland. WATL Study Group. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheitan. , 1998, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[90]  N. Siafakas,et al.  Pneumothorax as a first manifestation of sarcoidosis. , 1997, Chest.

[91]  R. Crystal,et al.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis. , 1990, The Journal of clinical investigation.

[92]  R. Young,et al.  Sarcoidosis--the beginning: historical highlights of personalities and their accomplishments during the early years. , 1984, Journal of the National Medical Association.

[93]  R. Crystal,et al.  Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. , 1983, The New England journal of medicine.

[94]  J. Scadding The late stages of pulmonary sarcoidosis , 1970, Postgraduate medical journal.

[95]  J. Scadding Prognosis of Intrathoracic Sarcoidosis in England , 1961, British medical journal.

[96]  S. Lofgren The concept of sarcoidosis. , 1961, American Review of Respiratory Disease.

[97]  K. Wurm [The significance of stage classification of sarcoidosis (Boeck's disease]. , 1960, Deutsche Medizinische Wochenschrift.

[98]  W. Röntgen,et al.  ON A NEW KIND OF RAYS. , 1896, Science.

[99]  B. Barna,et al.  Inflammatory Pathways in Sarcoidosis. , 2021, Advances in experimental medicine and biology.

[100]  D. Okada,et al.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis , 2018, Circulation. Cardiovascular imaging.

[101]  R. Baughman,et al.  Predictors of Mortality in Pulmonary Sarcoidosis , 2018, Chest.

[102]  Pallewatte Pictorial essay , 2016 .

[103]  A. Dupuy,et al.  [Heerfordt's syndrome]. , 2005, Presse medicale.

[104]  G. Meier,et al.  Zur Prognostik der Sarkoidose (Morbus Boeck) , 2005, Beiträge zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung.

[105]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[106]  R. Crystal,et al.  Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. , 1982, Thorax.

[107]  S. Lofgren,et al.  The bilateral hilar lymphoma syndrome; a study of the relation to tuberculosis and sarcoidosis in 212 cases. , 1952, Acta medica Scandinavica.